Exploring Oncology Clinical Design
Webinar date & time: March 9th 14:00 CET
Join us for an engaging and educational webinar on the topic of “Exploring Oncology Clinical Design”. This webinar will provide you with valuable insights and the latest information on oncology clinical design.
You’ll have the opportunity to hear from expert speakers who will share their experience and knowledge on the subject. Whether you’re a healthcare professional, researcher, or simply interested in the field of oncology, this webinar is a must-attend event. Register now to secure your spot!
The webinar will lead by our field experts, who share their experiences and best practices. So let’s dive in and explore the complexities and opportunities of Oncology Clinical Trial Design.
During the webinar we’ll discuss:
- Dose escalation designs
- Early phase study – endpoints
- Protocol – schedule of assessment considerations
Register here!
Regina Auskalnienė - MD
Chief Global Clinical Research Officer
Regina Auskalniene is a Medical Doctor, cardiologist. She has over 13 years of experience in Clinical Research and has been leading our Clinical Operations department since April 2018, overseeing Clinical Monitoring, Project Management and Start-up activities in the region.
Read more.
Vladimir Mukovozchik, MD
Head of Project Management
Vladimir has over 16 years of experience in clinical research. He has been working in global CROs on managerial roles for many years and has been leading our project management department since 2022. He has extensive experience in different therapeutic areas with the main expertise lying in the oncology field.
Planning Your Next Oncology Trial?
Let’s talk how we can help you design oncology trials that get you the results you need to improve patient lives.
Other content that might interest you:
What do you need to know while preparing RMP for EAEU and CIS region?
Preparation of Risk Management Plan (RMP) for a specific medicinal product usually is the responsibility of the Qualified Person Responsible for Pharmacovigilance (QPPV) and its team. Thus, QPPVs and their team’s should be familiar with legislation requirements for RMP preparation in different regions. Within this article, we will concentrate on the Eurasian Economic Union (EAEU) and identify specific conditions of EAEU countries as well as to try to understand the expectations of Competent Authorities in this region.
MAH is the Key to the Pharmacovigilance: 10-year Lithuania Statistics
Even though the drug safety and reporting of the adverse effects is the responsibility of all Health Care Providers, pharmacists and patients, statistics show that the one in charge is Marketing Authorization Holder. During the National semi-annual conference „Pharmaceutical News“, State Medicines Control Agency presented the statistics of suspected ADRs reporting in Lithuania.
Biomapas appoints Head of Global Pharmacovigilance
March 2020 – Clinical, regulatory and pharmacovigilance solution provider to the global life science industry, Biomapas, appointed leading pharmacovigilance professional Martijn van de Leur as Head of Global Pharmacovigilance. With offices located in Lithuania, Switzerland, Sweden, Russia, Georgia, Ukraine and Poland, Biomapas provides services in 60+ countries across 4 continents. As a functional and full outsourcing solution provider, Biomapas continues to strengthen its international team and geographical coverage of its services globally.
